In the era of big data, integrative analyses that pool data from different sources are now extensively conducted in order to improve performance. Among many interesting applications, genomics research is an area where integrative methods become popular tools to identify prognostic biomarkers for various diseases. In this paper, we propose such a framework for pathway and gene identification. Our method employs a hierarchical decomposition on genes' effects followed by a proper regularization to identify important pathways and genes across multiple studies. Asymptotic theories are provided to show that our method is both pathway and gene selection consistent. More importantly, we explicitly show that pathway selection consistency needs milder statistical conditions than gene selection consistency, as it would allow false positives and negatives at the gene selection level. Finite-sample performance of our method is shown to be superior than other ad hoc methods in various simulation studies. We further apply our method to analyze five cardiovascular disease studies. Our method is intrinsically a general method on group-wise and element-wise selections from integrative analysis, which can have other applications beyond genomic research.
Introduction
High-throughput sequencing technology has become a prevalent tool in biological and medical research. A unique characteristic of the sequencing data is that they are high-dimensionallow-sample-size (HDLSS), i.e., the number of biomarkers is substantially greater than the number of participants in the studies. On the other hand, the decisive biomarkers regulating the phenotypes are usually sparse compared with the total number of biomarkers along the whole genome and their effects are often weak; making the results from individual studies unremarkable and hard to be reproduced [20] . For this reason, joint analysis of multiple genomic data has been used widely and proven to be essential for identifying decisive biomarkers. A good example is the discovery of the risk loci for type 2 diabetes [23, 32] .
There are two types of joint analysis. One is the classical meta-analysis that aggregates summary statistics from individual datasets to obtain an overall score, based on which statistical significance across all studies is assessed. A comprehensive review of meta-analysis and its applications in genomic studies can be found in [25] . The other is the integrative analysis using individual patient data (IPD) from multiple studies [15, 16, 17] . In the era of big data, IPD becomes more accessible from large genomic consortia such as Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA). The integrative analysis links phenotypes to gene expression via a joint model of multiple studies and employs variable selection techniques to select decisive genes. It explores the relationship between phenotypes and genes in a more direct way and aims to identify genes that can better predict the phenotypes. Compared with the traditional meta-analysis, it is more appealing as the raw data contain more information than the summary statistics.
Groups of genes, commonly referred to as pathways, are often involved in the same biological processes. The pathway information has been well documented in publicly available databases such as KEGG [21] and Gene Ontology [2] . Since pathways play more defined biological roles than individual genes, pathway analysis has been advocated for better comprehension of the biological mechanism of the disease process. [14] provided a review of pathway analysis approaches developed in the recent decade, including popular methods such as Gene Set Enrichment Analysis [24] and Over-Representation Analysis [10, 13] . Some recent advance in pathway analysis, e.g., a Bayesian method proposed in [3] , further considers within-pathway selections of genes. In addition to pathways, this method identifies a list of genes under selected pathways that are associated with the response. However, all the above methods only focus on the analysis of a single dataset.
To the best of our knowledge, there are no existing methods that conduct pathway and withinpathway selections based on joint analysis of multiple datasets. In this paper, we propose such a new integrative analysis that utilizes a novel decomposition on genes' effects to reflect the relationship between pathways and genes. This decomposition, together with sparsity-induced penalties, enable both pathway and gene selections. A main difficulty of pathway selection is that the effects of pathways are unobserved. We show that once a reasonable identifiability condition is assumed, whether a pathway has nonzero effect is definitive. Hence, the pathway selection is sensible.
Under our framework, the employment of pathway information offers substantial benefit in statistical properties of the proposed method. We explicitly show that pathway selection requires much weaker conditions to achieve desired asymptotic properties. The main reason is that correct selection of pathways can allow some false positives and negatives at the gene selection level (see Section 4) . In particular, for the pathway selection, we are able to avoid the irrepresentable condition that has been shown to be necessary for variable selection consistency in HDLSS settings, when either a convex or folded-concave penalty is used [6, 33] . The reason is that our penalty's subgradient is infinitely large at the origin, leading to the removal of unimportant pathways without the irrepresentable condition. In addition, we show that correct pathway selection requires weaker conditions on the minimal signal strength than correct gene selection.
The rest of the paper is organized as follows. In Section 2, we introduce our method. In Section 3, we discuss the estimation and computation of our method. In Section 4, we provide theoretical results regarding pathway and gene selection consistency, where conditions needed for the two types of consistency are explicitly compared. In Section 5, we discuss how our method deals with the issue of pathway overlapping. In Section 6, we examine the finite-sample performance of our method through simulation studies. Examples of both overlapping and non-overlapping 2 pathways are simulated. In Section 7, our method is applied to an integrative analysis of five cardiovascular studies. The paper is completed with a discussion in Section 8. All technical proofs are relegated to the Appendix.
A Hierarchical Decomposition for Pathway Selection
We consider M independent studies with n m subjects in study m. Let y mi be a binary phenotype of the ith subject in the mth study and x mi = (x mi,1 , . . . , x mi,d ) be the corresponding expression of d genes. Our proposed methods can be applied to data with any type of outcomes. We focus on the binary phenotype in this paper, because our motivational studies (see Section 7) have binary outcomes/phenotypes. It is natural to assume the following logistic regression model:
where α m is the intercept, β k jm is the effect of the jth gene under the kth pathway in the mth study, and they both are allowed to vary with m. K is the number of pathways and G k is the number of genes under the kth pathway. We assume pathways do not have overlapping genes until Section 5 in which we then discuss the case of overlapping pathways. We decompose β k jm into three components as
The parameter p k is the effect of the kth pathway among all studies; g k j is the effect of the jth gene under the kth pathway; ζ k jm is the gene's effect in the mth study. Such a decomposition is inspired by the hierarchical LASSO [34] , which targets for group selection within a single dataset. In decomposition (1), the exact values of p k , g k j and ζ k jm are not identifiable (since cp k · g k j ζ k jm /c = p k g k j ζ k jm for a nonzero constant c). However, as will be shown in Proposition 1, it is definitive whether they equal to zero once a reasonable identifiability condition is assumed. A natural definition of an important pathway across multiple studies is that at least one of its genes has nonzero effect in at least one study. More explicitly, the set of important pathways is defined as P = {k : there exists at least one ( j, m) such that β * k jm 0},
where β * k jm denotes the true effect. Next, we show that this definition is reasonable as it essentially requires an important pathway to have nonzero pathway effect, i.e., p * k 0. In fact, the true effect β * k jm can always be decomposed hierarchically as β *
where 0/0 is defined as 1. Even though the decomposition is not unique and therefore the exact values of (p pathway effect. Moreover, we show that P defined in (2) is the same as the support of p * (the set of nonzero elements of p * ), where p * = (p * 1 , . . . , p * K ) . In other words, we require an important pathway to have nonzero pathway effect. Proposition 1. It holds that P = {k : p * k 0}, under the following condition (C1) For any fixed (k, j), if β
Estimation and Computation
Let m (α m , p, g, ζ m ) be the log-likelihood of the mth study (divided by n m ) such that
where p = (p 1 , . . . , p K ) , g = (g 11 , . . . , g KG K ) , and ζ m = (ζ 11m , . . . , ζ KG K m ) . We impose L 1 penalties on p, g, ζ m and solve the following optimization problem:
where χ n is a positive tuning parameter,α = (α 1 , . . . ,α M ) andζ = (ζ 1 , . . . ,ζ M ) . The coefficient β k jm is then estimated byβ k jm =p kĝk jζk jm . Nonzeroβ k jm 's are considered as selected. Selection properties will be studied in Section 4. Remark 1. In problem (3), the tuning parameters in front of penalties on p and g can always be normalized to be 1, due to the fact that cp k · dg k j · (cd) −1 ζ k jm = p k g k j ζ k jm , for nonzero constants c and d.
Similar as (2), we define pathways selected by our method aŝ P = {k : there exists at least one ( j, m) such thatβ k jm 0},
In Proposition 2, we show thatP is the same as the support ofp. Theorem 1 in Section 4 shows that asymptoticallyP = P using definitions in (2) and (4). Therefore, it implies that {k :p k 0} = {k : p Proposition 2.P = {k :p k 0}.
To solve (3), we propose fitting p, g, ζ and α iteratively. We fix three parameters and solve for the other and iterate between the steps until the algorithm converges. At each step, (3) is a convex problem, which can be efficiently solved by the coordinate descent algorithm [8, 29] . The value of the objective function decreases after each iteration, hence the convergence is guaranteed. Let X m ∈ R n m ×d be the matrix containing data from the mth study. Denote H ∈ R d×K as the indicator matrix of the membership of genes in different pathways such that its ( j, k)th element h jk = 1 if the jth gene belongs to the kth pathway and h jk = 0 otherwise. Letα (s) ,p (s) ,ĝ (s) , andζ (s) be the solutions of α, p, g and ζ at the sth step. We elaborate the algorithm as follows.
The algorithm of solving (3):
Step 1. For each dataset, standardize columns to have zero mean and unit variance. Initializê g (0) and Hp (0) , e.g., letĝ (0) = 1 and
Step 2. In the sth iteration, letX m = X m ·ĝ (s−1) · Hp (s−1) , where · represents product by columns. Denote
Step 3. UpdateX m by lettingX m = X m ·ζ
m is the subvector ofζ (s) for the solutions in the mth dataset. Let
Step
where z mk is the (m, k)th element of Z m . Solvê
Step 5.
Step 6. Letβ
k jm . Return to step 2 and iterate, unless the difference between the values of the objective functions in (3) at two consecutive steps is less than some predefined threshold.
Next, we show that (3) has an equivalent form in terms of the original coefficient β k jm .
Lemma 1. The problem (3) is equivalent to
The equivalent form (5) describes our method in a different perspective. It shows that our method penalizes the negative log-likelihood with different penalties at different levels of the coefficients. Regarding M m=1 |β k jm | as the overall effect of the jth gene under the kth pathway across M studies, it penalizes the gene's overall effect with an L 1/2 -penalty. At the pathway level, an L 1/3 -penalty is imposed. Due to the singularities of L 1/2 and L 1/3 penalties at the origin point, our method can select pathways as well as its important members. In addition, the L 1 -penalty on the genes' effects in individual studies enables across-study selection for each gene and adapts to the heterogeneity among the studies. Due to the equivalence, (5) will be used to establish the theoretical results in Section 4.
It is easy to see that (5) is a non-convex problem thus hard to solve directly. However, due to the equivalence, it can be transferred into a sequence of convex optimization problems by using (3). This is another benefit brought by the hierarchical decomposition.
Theoretical Properties
We present two results regarding the pathway and gene selection accuracy of our method. The results are considered for fixed M, but d and K can diverge with n, as long as log d = o(n).
To simplify the presentation, we assume each dataset has n observations and the intercept terms {α * 0m } M m=1 are all 0. We begin with introducing some notation. For any vector a ∈ R d , let a 1 = d j=1 |a j | be the L 1 -norm of a and a ∞ = max j |a j | be the sup-norm of a. Define the support of a as { j : a j 0}. For a symmetric matrix A ∈ R d×d , let A ∞ = max i d j=1 |a i j | be the matrix sup-norm of A. For two matrices A and B, denote A • B as the Hadamard (componentwise) product of A and B. In addition, denote a S as the sub-vector of a with indices in S and A S as columns of A with indices in S . In particular, we denote k j· as the set of {k j1, . . . , k jM}. For a set S , we denote |S | as its cardinality.
Pathway selection consistency
According to (2) , to ensure that an important pathway is selected, it suffices to select one of its members in at least one study. In fact, we show that the member with the largest overall effect can be selected with large probability, where the overall effect of a gene is defined as the L 1 -norm of its effects in all studies. To this end, it only requires the largest overall effect not to be small, which is much weaker than the typical assumption on the minimal signal strength. On the other hand, as will be seen in the proof of Theorem 1, the unique property of the penalty term in (5) (its subgradient is infinitely large at the origin point) ensures that unimportant pathways are ruled out 6 without additional assumptions. This is not like the L 1 or other folded-concave penalties, where irrepresentable conditions are needed [6, 33] .
To present the result, let K * = M|P|, the number of important pathways multiplied by M, and
the collection of |P| genes' effects in M studies, whose overall effect is the largest in their own pathways. Denote B = min k∈P, j:k j·∈J β * k j· 1 /2, the minimal overall effects of these |P| genes. We write B and K * in terms of orders of n as B n −α B and K * n −α K * . We present (5) in a matrix form as
where X ∈ R Mn×Md is the block-diagonal design matrix, whose mth block contains data from the mth study, Y = (y 11 , y 12 , . . . ,
, e is a vector with all elements equal to 1, the penalty term
n .
Theorem 1. Assume the following conditions hold.
where
, and τ n = min δ∈N λ min (n −1 X J Σ(X J δ)X J ), then for sufficiently large n, with probability greater than 1 − 2K * /n, there exists a solutionβ to (5), such that (a)P = P;
, where c is a generic positive constant and γ is some number that is arbitrarily smaller than 1/2. Remark 2. Theorem 1 implies that our method is asymptotically pathway selection consistent and the corresponding estimation of β * J is uniformly consistent. In general, conditions needed for pathway selection consistency is weaker than that for gene selection consistency (see Theorem 2). For example, condition (C2) only requires the minimum of the largest overall effects under important pathways not to be small, compared with a stronger condition (C6) needed for gene selection consistency. Moreover, Theorem 1 does not need the irrepresentable condition [6, 33] to reach pathway selection consistency, while this condition (C9) is needed to achieve gene selection consistency. The intuition is that, pathway selection consistency is easier to be achieved than gene selection consistency. For important pathways, correct pathway selection can tolerate false positive and negative selections of their genes, as long as at least one gene under the important pathway is selected in at least one study. For unimportant pathways, our method is able to remove them without an irrepresentable condition due to the fact that the subgradient of our penalty at the origin is infinitely large.
Gene selection consistency
If stronger conditions are satisfied, we show that our method is further gene selection consistent in every study in the sense that the support ofβ is the same as that of β * . The genes' effects are often heterogeneous among various studies due to many practical factors, such as various types of biospecimens, inconsistent experimental environments, etc. For this reason, we allow a gene's effect to be zero in some studies but nonzero in others. The nonzero effects are also allowed to vary. The challenge of achieving gene selection consistency is, for genes have zero/nonzero effects in different studies, to identify the studies where the gene has zero effect. The gene selection consistency is stronger than pathway selection consistency, since the former implies the latter.
To present the result, we divide elements of β * into three subsets:
Denote s = |I|, the cardinality of set I and
The magnitudes of b, s, d are quantified in the order of n as b n −α b , s n α s , and log d n α d , where α s , α u and α d are positive numbers.
Theorem 2. Under the following conditions
If we choose the penalty λ n such that (n
, and λ n κ 0n = o(τ 0n ), where
and τ 0n = min δ∈N 0 λ min (n −1 X I Σ(X I δ)X I ), then for sufficiently large n, with probability greater
, where c is a generic positive constant and γ is some number that is arbitrarily smaller than 1/2.
Pathway overlap
So far, we have assumed that pathways do not have overlapping genes. In practice, pathways can share some common genes and this makes the analysis and interpretation much more 8 challenging than the non-overlap case. In general, one can always classify any pathway into the following three cases according to whether its important member genes are shared with some other pathways. For a pathway that has at least one exclusive important gene (a gene that only belongs to that pathway and its effect is nonzero in at least one study), it is important according to definition in (2). For a pathway whose genes all have zero effects, it is unimportant. For a pathway whose important genes are all shared with other pathways, its importance is unclear.
The reason is that the shared genes' contribution in different pathways is undetermined even if its total effect is known. Hence, if a pathway's importance cannot be judged by its exclusive genes, its importance is not always identifiable.
To quantify the distribution of the shared gene's effects in different pathways, we use the following assumption. Suppose
Under condition (C11), this shared gene's effect can be decomposed as (p k 1 + · · · + p k T )gζ m . Its contribution in pathway k is proportional to the pathway effect p k . Once condition (C11) is assumed, our algorithm in Section 2 still works for the overlapping case and gives a pathway effect estimatorp. We select pathways by referring to the nonzero elements ofp. As for gene selection, when a shared gene is selected, our algorithm tells under which pathways the gene is selected (by referring to nonzero elements ofp).
In reality, the overlapping scheme of pathways can be complex. The asymptotic properties are difficult to establish under this setting. We leave it as a topic for future research. Nevertheless, we investigate the empirical performance of our method under this setting by simulation studies, where overlapping pathways for the first two definitive cases are simulated.
Simulation Studies
We simulate scenarios of non-overlapping and overlapping pathways to inspect our method's finite-sample performance.
Non-overlapping pathways
We simulate M = 10 studies with sample size n m = 50 in each study. The expression of d = 100 genes from K = 20 pathways are simulated, with 5 genes in each pathway. The gene expression of the ith subject in the mth study x mi are i.i.d. from N 100 (0, I). The corresponding phenotype y mi is generated from the logistic model
2 ) with ν 1 = 8, ν 2 = 8, ν 3 = −4, ν 4 = −4, ν 5 = −8, and a k = 0 for k > 5; b k j is i.i.d from Bernoulli(π g ); and c k jm is i.i.d from Bernoulli(π m ). That is, only the first five pathways are important. Each gene under the important pathway has probability π g to be important. For an important gene, it has probability π m to be important in the mth study. The probabilities π g and π m control the heterogeneity among genes and studies, respectively. We chose two values (0.3 and 0.9) for both π g and π m to represent different levels of heterogeneity. Simulations were repeated for 100 runs.
Our method is compared with two ad-hoc selection methods: 9
Separate Group LASSO (seGLASSO): it runs study-by-study selections by treating genes under each pathway as a group and imposes a Group LASSO penalty therein, i.e., in each study it solves the problem
where λ m is a positive tuning parameter.
Stack Group LASSO (stGLASSO): it stacks data in all studies and penalizes the total negative log-likelihood with a Group LASSO penalty, i.e., it solves the problem argmin
where λ is a positive tuning parameter.
The optimal tuning parameters in the three methods are all selected by minimizing the Bayesian Information Criterion. The three competitors' performance is assessed by their selection capability of pathways and genes. Two measurements will be presented: (a) Sensitivity: the proportion of important pathways/genes being selected; (b) Specificity: the proportion of unimportant pathways/genes not being selected. In particular, the set of important pathways is {1, . . . , 5}. The set of important genes is defined as {(k, j, m) : β * k jm 0}. Figure 1 gives the boxplots for pathway and gene selection among the 100 simulations. The overall performance is measured by both sensitivity and specificity. Tables 1 and 2 give the means of sensitivity and specificity. These results clearly show that the pathway selection by our method is the best in all settings. The gene selection is also the best when studies are heterogeneous (π m = 0.3) and comparable to stGLASSO when studies are homogeneous (π m = 0.9). The seGLASSO performs badly as it uses one data at a time and does not borrow strength across studies. The performance of stGLASSO changes drastically in different settings. When π m is small, it performs badly as it does not take study heterogeneity into account. Even when π m is large, its performance of pathway selection is still worse than ours. In conclusion, our method performs consistently well for various settings in terms of both pathway selection and gene selection accuracy.
The computational speed of our estimator is comparable to that of seGLASSO and stGLASSO. From the algorithm in Section 3, each iteration of our method solves a convex optimization, similar to seGLASSO and stGLASSO. In the simulations, we noticed that our method usually took very few iterations to convergence.
Overlapping Pathways
We simulate three more examples for pathways with overlapping genes. We simulate M = 5 studies with sample size n m = 30 in each study, the number of pathways K = 21 and the number of genes d = 100. The gene expression values x mi are generated in the same way as Section 6.1. The true effects of genes are generated by letting β * k jm = p * k g * k j ζ * k jm and the following three cases are considered. Table 3 gives the genes' effects for the first four pathways. The unlisted genes have zero effects. In Example 1, the first four pathways are important and three of them share some common genes. In Example 2, only pathways 1, 2, and 4 are important. Even though pathway 3 is unimportant, it shares two genes (gene 6 and 7) with an important pathway (pathway 2). We design such an example to see how well our method could remove an unimportant pathway, which overlaps with an important one. In Example 3, gene 3 and 4 are shared by all the four important pathways. Figure 2 gives the proportion of each pathway being selected among 100 simulations. Table 4 gives the means of sensitivity/specificity of pathway and gene selection. Figure 2 shows that our method can correctly distinguish important and unimportant pathways. For the challenging case of Example 2, our method correctly selects pathway 2 and removes pathway 3, even though they share two common genes. For the other challenging case of Example 3, our method correctly selects the first four pathways, even though two genes are shared by all of them. 
7. An integrative analysis of five cardiovascular disease studies
For further illustration, we applied our method to an integrative analysis of five cardiovascular disease (CVD) studies. These studies were aimed to identify biomarkers that are associated with immune response in the development of atherosclerosis. The phenotypes in these studies are binary. The case groups are patients showing certain atherosclerotic syndrome, e.g., having had ischemic strokes. The control groups are healthy people. All subjects were sequenced using microarrays. The raw data can be found on Gene Expression Omnibus with accession names "GSE12288", "GSE26561", "GSE20129", "GSE22255", and "GSE28829". Table 5 presents more details of the five studies. However, a careful inspection of their original findings revealed that these studies identified completely different sets of genes. Therefore, the underlying genomic mechanism is still largely unknown. It also indicated that the gene selections from case-by-case studies are hard to be reproduced. This motivated us to incorporate external pathway information and integrate the data sets. We cross-referenced the genes with the pathway information listed on the Kyoto Encyclopedia of Genes and Genomes (KEGG). In total, 4156 genes in 210 pathways from KEGG were involved in the analysis. We applied our method to select pathways as well as their important member genes.
Eleven pathways were identified. Table 6 gives the selected pathways and genes. Table  7 gives the selected genes in each individual study. Among the selected pathways, "Antigen process and presentation", "Hedgehog signaling", "Osteoclast differentiation" and "Phagosome" were known to control key modules for activating human body's immune system [12, 22, 27, 30] . These pathways can certainly be triggered by inflammation. Epidemiological and clinical studies have shown strong and consistent relationships between markers of inflammation and risk of cardiovascular events [28] . Moreover, "Ubiquitin mediated proteolysis", "mRNA surveillance" and "Protein processing in endoplasmic reticulum" play important roles in a broad array of basic [4, 9] . "Axon guidance" was previously identified to regulate molecules for the angiogenic growth of blood vessels [1] . The "peroxisome proliferator-activated receptor" (PPAR) was shown to be an important regulator of cardiac metabolism [7] . Elevated circulating levels of "cytokines and/or cytokine receptors" was also known to predict adverse outcomes in patients with heart failure [5] . These key pathways were identified by our method. In addition, Huntington's disease patients were known to have higher risk of CVD, presumably as a result of accumulation of toxic amyloid-like inclusions [18] . Our selection of "Huntington's disease" pathway indicates that Huntington's disease and CVD can share some common prognostic biomarkers. Moreover, we used the pathway enrichment score proposed in [19] to assess how our selection of pathways is enriched. In particular, for each selected pathway, we created a 2 × 2 contingency table of the number of genes selected in and out of that pathway. Then, we tested whether that pathway is over-represented by the Fisher's exact test. The corresponding p-values were used as the enrichment scores, where smaller p-values indicate stronger evidence that the selected pathway is enriched. We calculated pathway enrichment scores in each individual study as well as over all five studies together. Table 6 gives the results of the enrichment scores. It clearly indicates that the selected pathways become more enriched when the integrative method is applied over multiple studies than their appearance in a single study.
In conclusion, our integrative method identified more key biomarkers than the original individual studies. The resulting pathway selections become more enriched. Both results necessitate our proposal of integrating data and pave the way for further studies of the interactions among the identified biomarkers.
Discussion
In this article, we have provided a general framework of enhancing the integrative analysis with pathway information, which selects pathways as well as their functioning genes. The incorporation of pathway information not only improves the biological interpretation of the results but also brings statistical advantage. We adopt a hierarchical decomposition on gene effects and show that whether a pathway has nonzero effect is determined once a reasonable identifiability condition is assumed. We show that our method can consistently select both pathways and 15 GSE12288 ACP5, ANAPC2, ATP5B, BMP2, BMP6, CANX, CAPN1, CSNK1D,  CXCR3, DERL2, EDAR, HLA-A, HSPH1, LILRB4, NDUFA4L2, RELB,  SEMA6C, TRIM37  GSE16561 ANAPC13, ATP5B, CANX, CSNK1D, DNAI2, RXRG  GSE20219 ACP5, ANAPC13, BMP6, CAPN1, CXCR3, EDAR, GAB2, GK, HLA-DRA, IFNA4, IL21R, INHBA, INHBE, NUDT21, UBE3C  GSE22255 ANAPC13, ATP5B, CANX, EDAR, PPIL2, RXRG  GSE28829 ACP5, ANAPC13, ANAPC2, PPIL2 genes. The pathway selection requires weaker minimal signal strength condition which allows some false positives and negatives at the gene selection level, thus avoids the restrictive irrepresentable condition. Such advantages have been explicitly quantified in our theoretical results.
Our method can also be adapted to certain new scientific information. For example, for some pathways, their genes tend to be all upregulated or downregulated. Such information can be easily built into our method by requiring g k j ≥ 0 and ζ k jm ≥ 0 for such a pathway k. These constraints can be added to Steps 2 and 3 of our algorithm at minimum extra computational cost. Once they are incorporated in the algorithm, our solution guarantees that the effects of genes under such pathways will be concordant. The L 1 penalty on the decomposed parameters imposed in (3) is not the only choice. If the studies being integrated are more homogeneous, the L 1 penalty on ζ can be replaced by the L 2 penalty. In this way, our method will select genes in an "all-in-or-all-out" fashion, meaning that a gene is either effective in all studies or not effective at all.
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Appendix. Proofs
Proof of Proposition 1. First, if p * k = 0, then β * k jm = 0. Hence, it is obvious that {k : p * k 0} c ⊂ P c . On the other hand, by the definition of P and the identifiability condition (Condition 1),
Proof of Proposition 2. Sinceβ k jm =p kĝk jζk jm ,p k = 0 impliesβ k jm = 0 for all j = 1, . . . , G k and m = 1, . . . , M. Hence, {k :p k 0} c ⊂P c . On the other hand, ifβ k jm = 0 for all j and m, since (p k ,ĝ k j ,ζ k jm ) minimizes (3), it must hold thatp k =ĝ k j =ζ k jm = 0, otherwise (0, 0, 0) will give a smaller value of the objective function in (3).
Proof of Lemma 1. Referring to the main body of the paper, under decomposition (2), (3) is equivalent to
, the above problem is further equivalent to
Next, we show that (A.1) is equivalent to
In fact, it holds trivially that any solution of (A.1) is also a solution of (A.2). On the contrary, if (p k ,ĝ k j ,ζ k jm ) is a solution of (A.2), then
is a solution of (A.1). Hence (A.1) and (A.2) are equivalent in the sense that there is an oneto-one correspondence between their solutions. By Lagrange multiplier, (A.2) is equivalent to minimizing
Then, we have
(A.5) implies that α k jm = χ n /|p k g k j |, which together with (A.4) give |g k j | = χ n M m=1 |ζ k jm |. Then, it follows from (A.3) that
Hence,
This together with
This together with (A.6) show that
Hence, (3) and (5) are equivalent.
Proof of Theorem 1. We show that there exists a solutionβ to (5) such that its restriction on set J, i.e.,β J , satisfies (b), and all other elements are 0. Then, by definition, this solution also satisfies (a). By optimization theory, the vectorβ satisfies the following Karush-Kuhn-Tucker (KKT) conditions is a solution to (6) .
Since y mi ∈ {0, 1} and columns of X have been standardized to have norm n 1/2 , by Proposition 4(a) of [6] ,
where ξ k jm is the (k, j, m)th element of ξ. Then, by the union bound,
In the event E, we show two results: [1] within the hypercube M := {β : β − β J ∞ ≤ cn −γ }, there existsβ J ∈ R K * that satisfies (A.7) and (A.9); [2]β = (β J , 0) satisfies (A.8). These two results together with the KKT conditions and (A.11) complete the proof.
[1] Let η = nλ n ∇ρ(β), where the element η k jm = (1/6)nλ n β k j· where ∇ρ(β k jm ) = τ k j (β k j· )sign(β k jm )/6 for (k, j, m) ∈ I, ∂ρ(β k jm ) ∈ (−τ k j (β k j· )/6, τ k j (β k j· )/6), for (k, j, m) ∈ II, τ k j (β k j· ) = In event E 1 ∩ E 2 , we show two results: [1] within the set M 0 := {β ∈ R s : β − β * I ∞ ≤ cn −γ }, there exists a vectorβ I ∈ R s satisfying (A.15) and (A.17); [2]β = (β I , 0) satisfies (A.16). These two steps together with the KKT conditions complete the proof.
[1] Let η = nλ n ∇ρ(β), where η k jm = nλ n τ k j (β k j· )sign(β k jm )/6. Under Condition 7, Similarly as in (A.12) we have β * k j· 1 > 2 β * k j· − β k j· 1 and further β k j· 1 ≥ β * k j· 1 /2. Therefore, 6|η k jm | = nλ n τ k j (β k j· ) ≤ nλ n τ k j (β * k j· ). Hence, η ∞ ≤ nλ n h n . Therefore, (A.24) holds.
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